Suppr超能文献

米黑根毛霉天冬氨酸蛋白酶与抑胃酶肽A复合物在2.7埃分辨率下的结构。

Structure of the Rhizomucor miehei aspartic proteinase complexed with the inhibitor pepstatin A at 2.7 A resolution.

作者信息

Yang J, Quail J W

机构信息

Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan S7N 5C9, Canada.

出版信息

Acta Crystallogr D Biol Crystallogr. 1999 Mar;55(Pt 3):625-30. doi: 10.1107/s0907444998013961.

Abstract

Crystals of Rhizomucor miehei aspartic proteinase (RMP) complexed with pepstatin A grew in the orthorhombic space group P212121 and were isomorphous to native RMP crystals. The unit-cell dimensions are a = 41.52, b = 50.82, c = 172.71 A. There is one RMP-pepstatin A complex per asymmetric unit. The structure of the RMP-pepstatin A complex has been refined to a crystallographic R value of 19.3% and an Rfree value of 28.0% at 2.7 A resolution. A pepstatin A molecule fits into the large substrate-binding cleft between the two domains of RMP in an extended conformation up to the alanine residue at the P2' position. The dipeptide analogue statine residue at the P3'-P4' position forms an inverse gamma-turn (P3'-P1') with the statine residue at the P1-P1' position and its leucyl side chain binds back into the S1' subsite. The inhibitor interacts with the residues of the substrate-binding pocket by both hydrogen bonds and hydrophobic interactions. The hydroxyl group of the statine residue at the P1-P1' position forms hydrogen bonds with both catalytic aspartate residues (Asp38 and Asp237). This conformation mimics the expected transition state of the enzyme-substrate interaction. The binding of the inhibitor to the enzyme does not produce large distortions of the active site. No domain movement was observed compared with the native enzyme structure. However, the surface-flap region (residues 82-88) undergoes a conformational change, moving toward the inhibitor and becoming rigid owing to the formation of hydrogen bonds with the inhibitor. B-factor calculations of the two domains suggest that the C-terminal domain becomes more rigid in the complex than in the native structure.

摘要

米黑根毛霉天冬氨酸蛋白酶(RMP)与胃蛋白酶抑制剂A形成的复合物晶体属于正交晶系空间群P212121,且与天然RMP晶体同晶型。晶胞参数为a = 41.52,b = 50.82,c = 172.71 Å。每个不对称单元中有一个RMP - 胃蛋白酶抑制剂A复合物。RMP - 胃蛋白酶抑制剂A复合物的结构在2.7 Å分辨率下已精修至晶体学R值为19.3%,Rfree值为28.0%。一个胃蛋白酶抑制剂A分子以伸展构象嵌入RMP两个结构域之间的大底物结合裂隙中,直至P2'位置的丙氨酸残基。P3' - P4'位置的二肽类似物静抑素残基与P1 - P1'位置的静抑素残基形成反向γ - 转角(P3' - P1'),其亮氨酰侧链回折进入S1'亚位点。抑制剂通过氢键和疏水相互作用与底物结合口袋的残基相互作用。P1 - P1'位置静抑素残基的羟基与两个催化天冬氨酸残基(Asp38和Asp237)均形成氢键。这种构象模拟了酶 - 底物相互作用的预期过渡态。抑制剂与酶的结合未使活性位点产生大的畸变。与天然酶结构相比,未观察到结构域移动。然而,表面侧翼区域(残基82 - 88)发生构象变化,向抑制剂移动并因与抑制剂形成氢键而变得刚性。两个结构域的B因子计算表明,在复合物中C末端结构域比在天然结构中更刚性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验